(byoo DES oh nide)
- Budesonide Foam
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Uceris: 2 mg/actuation (33.4 g) [contains cetyl alcohol, edetate disodium, propylene glycol]
Brand Names: U.S.
- Corticosteroid, Rectal
Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation. Has potent glucocorticoid activity and weak mineralocorticoid activity.
Rectal foam: Minimal; Rectal enema [Canadian product]: Rapid and essentially complete within 3 hours
Vd: 2.2 to 3.9 L/kg
Extensive hepatic metabolism, primarily by CYP3A4 to 2 major metabolites (negligible glucocorticoid activity)
Urine: Oral dose: ~60%; Feces: ~30%
Time to Peak
Rectal enema [Canadian product]: 1.5 hours
Rectal enema [Canadian product]: 2 to 3 hours
85% to 90%
Use: Labeled Indications
Ulcerative colitis: Remission induction in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge
Entocort Enema [Canadian product]: Management of distal ulcerative colitis (rectum, sigmoid, and descending colon)
Hypersensitivity to budesonide or any component of the formulation
Entocort enema [Canadian product]: Known hypersensitivity to budesonide or any component of the formulation; imminent bowel perforation as well as the probability of obstruction, abscess or other pyogenic infection, fresh intestinal anastomoses, extensive fistulas and sinus tracts; systemic or local bacterial, fungal, or viral infections; active tuberculosis
Initial: 2 mg (one metered dose) twice daily for 2 weeks.
Maintenance: 2 mg (one metered dose) once daily for 4 weeks.
Rectal enema [Canadian product]: Initial: ~2 mg (one enema) once daily at night prior to bedtime for 4 weeks; if remission is not induced may continue for additional 4 weeks (total therapy duration: 8 weeks)
Refer to adult dosing.
Dosing: Renal Impairment
Rectal foam: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, dosage adjustment unlikely due to low systemic absorption.
Rectal enema [Canadian product]: There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Hepatic Impairment
Mild impairment (Child-Pugh class A): No dosage adjustment necessary.
Moderate or severe impairment (Child-Pugh class B or C): There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption. Monitor for increased signs and/or symptoms of hypercorticism; discontinue use if signs or symptoms are observed.
Rectal enema [Canadian product]: There are no dosage adjustments provided in the manufacturer's labeling.
Enema [Canadian product]: Remove nozzle and protective cap from enema bottle; place one dispersible tablet into enema bottle. Place nozzle back on the bottle, ensure protective cap is secured, then shake bottle vigorously for at least 10 seconds or until tablet is completely dissolved (suspension should turn slightly yellowish). Volume of reconstituted enema is 115 mL.
Rectal: Rectal foam: For rectal use only; not for oral use. Wash hands before and after use. Prior to use, patients should use the bathroom to empty the bowel. Attach applicator to canister nozzle. Each applicator is coated with a lubricant. If additional lubrication is needed, petrolatum or petroleum jelly can also be used. Warm the canister in the hands while shaking it vigorously for 10 to 15 seconds prior to use. Unlock the canister by twisting the domed canister top until it is aligned with the nozzle. May be used in a standing, lying or sitting position (eg, while sitting on the toilet). Turn the canister upside down and gently insert applicator tip into rectum as far as is comfortable. Push down on the pump dome with forefinger and hold for 2 seconds; release finger pressure on pump dome and hold applicator in place for 10 to 15 seconds. Only use applicator provided by manufacturer; do not insert any part of the aerosol container in the rectum. After administering, withdraw and discard the used applicator in provided plastic trash bag. Evening doses should be applied immediately prior to bedtime. Patient should try not to empty the bowel again until the next morning. Avoid fire, flame and smoking during and immediately following administration. Temporarily discontinue use before initiation of bowel preparation for colonoscopy; consult provider prior to resuming therapy.
Rectal enema [Canadian product]: For rectal use only; not for oral use. Patient should lie down on left side, shake the reconstituted enema bottle, remove protective cap and then empty contents into rectum. Patient should roll over on stomach and remain in this position for 5 minutes, then lie in a comfortable position. Enema should be retained the whole night if possible or as long as possible.
Avoid consumption of grapefruit or grapefruit juice during treatment
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not expose to heat or store at temperatures above 49°C (120°F). Do not refrigerate.
Enema [Canadian product]: Store at 15°C to 30°C (59°F to 86°F). Use immediately after preparation.
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Monitor therapy
CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Budesonide (Topical). Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased. Consider therapy modification
CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Topical). Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased. Consider therapy modification
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy
Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Frequency not always defined.
>10%: Endocrine & metabolic: Decreased plasma cortisol (17%)
1% to 10%:
Endocrine & metabolic: Adrenocortical insufficiency (4%), hpa-axis suppression, hypercorticism
Gastrointestinal: Nausea (2%)
<1% (Limited to important or life-threatening): Acne vulgaris, adrenal cortex hypofunction, agitation, allergic dermatitis, anaphylaxis, anxiety, depression, diarrhea, dizziness, drowsiness, dysphoria, emotional lability, fever, hyperacidity (peptic ulcer), hyperglycemia, hypertension, insomnia, pancreatitis, peripheral edema, pseudotumor cerebri, skin rash
Concerns related to adverse effects:
• Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in patients receiving high doses for prolonged periods, or with concomitant CYP3A4 inhibitor use. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. In situations where patients are subject to surgery or other stress situations, supplementation with systemic glucocorticoids is recommended.
• Impaired adrenal suppression in patients transferred from other glucocorticoids: Monitor patients transferred from systemic corticosteroids to corticosteroids with lower systemic effects (eg rectal foam), since steroid withdrawal, including benign intracranial hypertension or acute adrenal suppression, may occur. Replacement of systemic corticosteroids with rectal foam may unmask allergies (eg, rhinitis and eczema) previously controlled by systemic drug. Adrenocortical function monitoring may be required in these patients; reduce dose cautiously.
• Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; if exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG) may be needed; antivirals may be needed if chickenpox develops. Exposure to measles may require pooled intramuscular immunoglobulin use. Corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment). Use of Entocort enema [Canadian product] in patients with active TB is contraindicated.
• Cardiovascular disease: Use with caution in patients with hypertension, acute coronary disease, or limited cardiac reserve.
• Diabetes: Use with caution in patients with diabetes or a family history of diabetes; may alter glucose production/regulation leading to hyperglycemia.
• Gastrointestinal disease: Use with caution in patients with peptic ulcer disease. Use budesonide enema [Canadian product] with caution in patients with diverticulitis or severe ulcerative colitis (perforation risk).
• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; increased oral bioavailability has been reported in patients with cirrhosis.
• Myasthenia gravis: Use with caution; exacerbation of symptoms has occurred especially during initial treatment with systemic corticosteroids.
• Ocular disease: Use with caution in patients with cataracts and/or glaucoma or a family history of these diseases; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged glucocorticoid use.
• Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.
• Psychiatric disturbances: Systemic corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.
• Thyroid disease: Metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients.
Concurrent therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Elderly: Because of the risk of adverse effects, corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.
Dosage form specific issues:
• Flammable contents: Rectal foam contains flammable propellants. Avoid fire, flame and smoking during and immediately following administration. Temporarily discontinue use before initiation of bowel preparation for colonoscopy; consult health care provider prior to resuming therapy.
Baseline hepatic function tests; serum glucose, electrolytes; presence of infection, signs/symptoms of hypercorticism as clinically indicated
Pregnancy Risk Factor
Adverse events were observed in some animal reproduction studies. Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor. Oral budesonide has been used for the induction of remission in pregnant women with inflammatory bowel disease (Habal, 2012).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience flatulence, diarrhea, or nausea. Have patient report immediately to prescriber signs of high blood sugar (confusion, fatigue, increased thirst, increased hunger, polyuria, flushing, fast breathing, or breath that smells like fruit), signs of skin changes (acne, stretch marks, slow healing, or hair growth), signs of infection, buffalo hump, moon face, ankle edema, severe loss of strength and energy, dizziness, passing out, severe nausea, severe vomiting, bruising, bleeding, vision changes, joint pain, or bone pain (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about budesonide
- Budesonide (AHFS Monograph)
- Budesonide Capsule (FDA)
- Budesonide Inhalation Suspension (FDA)
- Budesonide (Oral Inhalation) (Wolters Kluwer)
- Budesonide (Systemic) (Wolters Kluwer)